Hematology/Oncology Pharmacy Association

Latest News

Tools and Resources Drug Updates

Pharmacist's Application to Practice: Cosibelimab-ipdl

March 03, 2025

Nathan Schieldt, PharmD, PGY2 Oncology Resident; William Morrissey, PharmD, PGY2 Oncology Resident; and Anna Clennon, PharmD, BCOP Clinical Pharmacist - all from Aurora St. Luke's Medical Center, Milwaukee, WI - write about cosibelimab-ipdl.

Tools and Resources Drug Updates

Pharmacist's Application to Practice: Zenocutuzumab-zbco

February 27, 2025

Allen Barry, MBA, PharmD Candidate Class of 2025, and Alisha Vora, PharmD, BCOP, CPP, Clinical Pharmacist Practitioner, Gastrointestinal Medical Oncology - both from the University of North Carolina, Chapel Hill, NC - write about zenocutuzumab-zbco.

Advocacy

HOPA Signs Letter in Support of Cancer Research Funding and Infastructure

February 21, 2025

Thirty-three organizations have signed a letter in support of cancer research funding amid Executive Orders that threaten the stability of research infastructure.

Advocacy Collaborations

HOPA, Bone Marrow & Cancer Foundation, and Walgreens Specialty Unite to Provide Oncology Pharmacy Education

February 07, 2025

HOPA, the Bone Marrow & Cancer Foundation (BMCF), and Walgreens Specialty Pharmacy have partnered on digital outreach resources and tools to support patients who are navigating the complexities of cancer treatment.

Membership

We Remain Committed to the Oncology Pharmacy Community and All Cancer Patients

February 06, 2025

The HOPA Board monitors recent Executive Orders and reaffirms the association's commitment to supporting our community of hematology/oncology pharmacists and all patients with cancer.

Tools and Resources

Development and Implementation of Oral Anticancer Agent Tools for a Thematic Quality Improvement Program

February 04, 2025

The HOPA OCC, with the participation of ASCO Quality Training Programs, has developed practice-based tools to aid in developing and improving initiatives and the care of patients receiving oral anticancer agents (OAAs).

Explore more from HOPA

Drug Updates

Pharmacist’s Application to Practice: Repotrectinib

January 25, 2024

Christopher L. Cornett II, PharmD PGY1 Acute Care Pharmacy Resident Anne E Hitron, PharmD, MS, MBA, BCOP ,Oncology Pharmacy Specialist, Baptist Health Louisville, Louisville, Kentucky

Journal Club

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

May 04, 2024

The data from this trial confirm that FTD–TPI plus bevacizumab is an effective treatment option for patients with refractory metastatic colorectal cancer, irrespective of mutational status, which side the tumor is on, and whether patients have previously

Late Breaking News

Clinical Oncology Pharmacy Technician: Impact of a New Role on Pharmacy and Patient Metrics at a Large Academic Cancer Center

September 20, 2024

A recently published article details the impact of having an inpatient clinical oncology pharmacy technician program.

Drug Updates

Pharmacist's Application to Practice: Momelotinib

January 11, 2024

Diana Mansour, PharmD, BCOP, Clinical Pharmacy Specialist, Charles M Gallagher, PharmD, PGY2 Oncology Pharmacy Resident; Kelsea Seago, PharmD, BCOP, Clinical Pharmacy Specialist, allfrom WVUH Hospitals, write about Momelotinib.

Journal Club

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

October 23, 2023

Amivantamab–chemotherapy improved PFS and intracranial PFS versus chemotherapy.

Late Breaking News

Oncology Stewardship Practice in the United States: A Hematology/Oncology Pharmacy Association National Survey

November 26, 2024

A recently published survey looks to gain insight on the current landscape of oncology stewardship in the United States.

uveal melanoma with unresectable hepatic metastases

Drug Updates

Pharmacist’s Application to Practice: Hepzato Kit™

January 11, 2024

Lainey Vargo, PharmD, PGY2-Oncology Resident Katie Murto, PharmD, BCOP and Crystal Heise, PharmD, BCOP WVUH Hospitals, Morgantown, West Virginia.

Journal Club

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

November 23, 2023

First-line treatment with osimertinib–chemotherapy led to significantly longer progression-free survival than osimertinib monotherapy among patients with EGFR-mutated advanced NSCLC.

Late Breaking News

Oncology Pharmacy Staffing Survey Across Practice Settings in the United States

September 19, 2024

The results of a recently published pharmacy staffing model survey has brought new insights into oncology pharmacy operations across the country.